Table 4.
Third-year cumulative rates and relative risks (RR) of p16/Ki-67, p16/mcm2, LBC and HPV16/18 genotyping for CIN2+
| Test results | N | Cumulative rate % (95% CI) | RR (95% CI) |
|---|---|---|---|
| p16/Ki-67 and p16/mcm2 | |||
| -/- | 111 | 1.80 (0.50-6.33) | Ref. |
| -/+ | 10 | 0.00 (0.00-27.75) | 1.02 (0.99-1.04) |
| +/- | 8 | 62.50 (30.58-86.31) | 34.69 (7.94-151.55) |
| +/+ | 21 | 71.43 (50.04-86.19) | 39.64 (9.78-160.72) |
| LBC | |||
| - | 127 | 11.02 (6.68-17.65) | 6.12 (1.42-26.33) |
| + | 23 | 34.78 (18.81-55.11) | 19.30 (4.38-85.06) |
| HPV16/18 | |||
| - | 140 | 12.14 (7.72-18.59) | 6.74 (1.59-28.55) |
| + | 10 | 50.00 (23.66-76.34) | 27.75 (6.15-125.21) |
Abbreviations: RR, relative risk; CI, confidence interval; LBC, liquid-based cytology; Ref, reference.